Incretin Atlas › Trials › HRS9531-203 (NCT06054698)
HRS9531-203 (NCT06054698)
Ribupatide (HRS9531) · obesity
Design
- Molecule(s)
- Ribupatide (HRS9531)
- Population
- obesity
- Phase
- 2
- Duration
- 36 weeks
- Registry
- NCT06054698
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8 mg | obesity china | 36 | — | −23.6 % | −22.8 % | — | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (2)
- 8 mg · weight_tp · press release
participants taking the 8 mg dose of HRS9531 achieved a mean weight loss of 22.8% (21.1% placebo-adjusted) at week 36
- 8 mg · weight_eff · press release
mean weight loss with the 8 mg dose of HRS9531 was 23.6% (21.7% placebo-adjusted)
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: HRS9531-203 (NCT06054698). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/hrs9531-203/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.